Clinical Trials in San Francisco

Showing 2801-2820 of 12,991 trials

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

NCT06104969

This study is a platform study designed to efficiently test multiple biomarkers to identify diabetic foot ulcers (DFUs) with a higher potential for healing versus not healing that ultimately could be applied at the point of care to drive personalized management decisions, and to better inform clinical trials of wound healing interventions

Diabetic Foot UlcerDiabetic FootDiabetes

University of Michigan5,000 participantsStarted Jun 2023

Tucson, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +5 more locations

COMPLETEDPhase 1< 1 mile

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

NCT03107988

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy in patients with relapsed/refractory neuroblastoma. The dose escalation phase of this study (Cohort A1) uses a traditional Phase I 3+3 design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 6 patients (Cohort B1), within which ALKi naïve patients will be prioritized, will be initiated. Parallel cohorts will be initiated in adults or patients with large BSA (Cohort A2) and in combination with chemotherapy upon establishing RP2D (Cohort B2).

Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium65 participantsStarted Sep 2017

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +10 more locations

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Find Trials by Condition in San Francisco

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Characterizing the Synergistic Effects of Physical and Cognitive Training on Attention and Working Memory

Accuracy of Pulse Oximeters With Profound Hypoxia During Motion

PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED

Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)

Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

SPRINT: Signature for Pain Recovery IN Teens

The Pediatric Artificial Pancreas Automated Initialization Trial

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System